Pharma Pulse 5/10/24: Medicare Advantage, Racing Along, Hits Some Speed Bumps, Anti-Obesity Drugs Global Strategic Business Report & more

Keytruda Combination Falls Short of Disease-Free Survival Primary Endpoint in Phase III Trial for High-Risk Endometrial Cancer

Findings from the Phase III KEYNOTE-B21 trial show that Keytruda (pembrolizumab) plus chemotherapy as adjuvant therapy, with or without radiotherapy, administered to patients with newly diagnosed high-risk endometrial cancer following surgery with curative intent did not achieve superiority in disease-free survival over placebo.

Medicare Advantage, Racing Along, Hits Some Speed Bumps

Enrollment has soared, but a relatively modest 2025 rate increase and changes to the Star rating system may lead plans to cut back on with their benefit offerings.

UK Armed Forces’ Data Is Exposed in Hostile Cyberattack

A payroll system used by Britain’s Ministry of Defense was targeted in a cyberattack that some lawmakers alleged was orchestrated by China.

Anti-Obesity Drugs Global Strategic Business Report 2024-2030

The global market for Anti-Obesity Drugs estimated at US$2.7 Billion in the year 2023, is projected to reach a revised size of US$4.8 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2023-2030.

UpScriptHealth on LinkedIn:

Our Founder & CEO Peter Ax shared insights with Pharmaceutical Executive about recent drug shortages and how digital solutions like UpScript can make a difference.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs